Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › nivolumab

nivolumab

57 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of nivolumab

285 trials tracked of nivolumab: 50 in phase 3 or 4 and 35 with published results. The most-cited published study has 3760 citations.

285Trials tracked
50Phase 3 & 4
0Recruiting
35With published results
Phase distribution
Phase 4 4 Phase 3 46 Phase 2 207 Phase 1 25 Other / NA 3
  1. Phase 3 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) Completed · 3,760 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,894 cited
  3. Phase 3 An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Completed · 2,588 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer Completed · 1,858 cited
  5. Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Completed · 1,511 cited
  6. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,391 cited
Show 44 more trials
  1. Phase 3 Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer Completed · 1,257 cited
  2. Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Completed · 1,250 cited
  3. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,222 cited
  4. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Completed · 1,111 cited
  5. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 812 cited
  6. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) Completed · 675 cited
  7. Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 530 cited
  8. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 516 cited
  9. Phase 3 Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer Completed · 364 cited
  10. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 271 cited
  11. Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Completed · 268 cited
  12. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 241 cited
  13. Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Completed · 241 cited
  14. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 219 cited
  15. Phase 3 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Completed · 188 cited
  16. Phase 3 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Completed · 184 cited
  17. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma Completed · 170 cited
  18. Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed · 165 cited
  19. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 161 cited
  20. Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Completed · 141 cited
  21. Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Completed · 112 cited
  22. Phase 3 A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Completed · 75 cited
  23. Phase 3 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread Completed · 73 cited
  24. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 43 cited
  25. Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma Completed · 32 cited
  26. Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 27 cited
  27. Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed · 26 cited
  28. Phase 3 A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Completed · 4 cited
  29. Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma Completed · 1 cited
  30. Phase 4 An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Completed
  31. Phase 4 Study of Nivolumab for Advanced Cancers in India Completed
  32. Phase 4 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India Completed
  33. Phase 3 Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Completed
  34. Phase 3 A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks Completed
  35. Phase 3 An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma Completed
  36. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
  37. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma Completed
  38. Phase 3 Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Completed
  39. Phase 3 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Completed
  40. Phase 3 A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia Completed
  41. Phase 3 Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Completed
  42. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  43. Phase 3 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection Completed
  44. Phase 3 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC Completed

Showing the 50 most-cited and recently-updated of 285 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
Diabetes & Endocrinology Sys. Review
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy The Hidden Reason Children's Brain Tumors Respond So Differently to Treatment
This narrative review examines the role of CSF1R inhibitors as precision immunotherapy for pediatric medulloblastoma subtypes.
Each subtype of children's brain tumors has a unique immune fingerprint, meaning matching treatment to that specific environment could drama…
Frontiers Apr 18, 2026
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Drug Pipeline RCT
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
Apr 18, 2026
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Oncology Phase II
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
Apr 16, 2026
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial
Gastroenterology Phase II
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
Apr 14, 2026
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer
Gastroenterology Phase I
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer Who Really Responds to a Stubborn Colon Cancer Combo?
A phase I trial in 29 patients with microsatellite-stable metastatic colorectal cancer tested the combination of regorafenib, ipilimumab, an…
A three-drug combo helped some patients with stubborn colon cancer, and immune markers now predict who will benefit most.
Apr 14, 2026
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab
ENT (Otolaryngology) Phase II
Low OT-NLR predicts superior survival in recurrent/metastatic HNSCC treated with cetuximab plus nivolumab A Simple Blood Ratio May Predict Cancer Drug Success
This Phase II clinical trial evaluated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) receiving combine…
A low white blood cell ratio found in blood tests predicts better survival and treatment response for advanced head and neck cancer patients…
Apr 13, 2026
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
Pulmonology & Critical Care Phase I
Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate New Drug Combo Helps Some Lung Cancer Patients Live Longer
A single-arm, open-label phase Ib/II trial in 52 patients with pretreated stage IIIB/IV NSCLC adenocarcinoma found a 6-month progression-fre…
A new drug pair safely extends life for some advanced lung cancer patients who previously tried immunotherapy or have high PD-L1 markers.
Apr 13, 2026
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients
Oncology Phase II
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Blood Apr 12, 2026
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Gastroenterology Phase II
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Apr 12, 2026
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges
Oncology Phase III
Review finds nivolumab improves survival across multiple cancers, highlights access and sequencing challenges Nivolumab improves survival for many cancers, but access and treatment planning remain challenges
A global review of nivolumab in patients with various malignancies reports better survival rates and subsequent regulatory approvals.
Nivolumab helps many cancer patients live longer, yet doctors still face hurdles in getting everyone the care they need.
Frontiers Apr 9, 2026
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Oncology Meta-analysis
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Frontiers Apr 9, 2026
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Allergy & Immunology Sys. Review
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Frontiers Apr 9, 2026